Lung Cancer in SLE: An Update

Authors

  • M. Kale Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, 687 Pine Avenue, V Building, Montreal, Quebec, H3A 1A1, Canada
  • A.E. Clarke Division of Rheumatology, University of Calgary, 3280 University Drive NW, Calgary, Alberta, T2N 4Z6, Canada
  • R. Ramsey-Goldman Northwestern University Feinberg School of Medicine, McGaw Pavilion, 240 E. Huron Street, Suite M-300, Chicago, IL 60611, USA
  • M. Urowitz Toronto Western Hospital, 399 Bathurst Street, IE-410B, Toronto, Ontario M5T 2S8, Canada
  • P.R. Fortin Service de Rheumatologie, Université de Laval, 2705, boulevard Laurier, Local S-763, Quebec G1V 4G2, Canada
  • S. Manzi West Penn Allegheny Health System, Allegheny General Hospital, Suite 295, 2nd Floor, South Tower, 320 East North Avenue, Pittsburgh, PA 15212, USA
  • M. Petri Johns Hopkins University School of Medicine, 1830 E. Monument Street, Suite 7500, Baltimore, MD 21205, USA
  • E. Ginzler State University of New York, Downstate Medical Center, 450 Clarkson Avenue, Box 42, Brooklyn, NY 11203, USA
  • S. Jacobsen Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark
  • O. Nived Lund University Hospital, S-22185 Lund, Sweden
  • C. Gordon College of Medical and Dental Sciences, University of Birmingham, Edgbaston B15 2TT, UK
  • J.-L. Senécal University of Montreal School of Medicine and Division of Rheumatology, Centre Hospitalier de l'Université de Montréal , 1560 East Sherbrooke Street, Montreal, Quebec H2L 4M1, Canada
  • D. Isenberg Department of Rheumatology, Faculty of Medicine, University College, 5 University Street, London WCIE 6JF, UK
  • S.-C. Bae Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul 133-792, South Korea
  • D.J. Wallace Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, 8737 Beverly Blvd, Suite 302, West Hollywood, CA 90048, USA
  • E. Yelin Department of Medicine, University of California, Suite 270, Laurel Heights Campus, San Francisco, CA 9413-0920, USA
  • D. Kamen Medical University of South Carolina, 36 Jonathan Lucas Street, Suite 912, Charleston, SC 29425, USA
  • A. Rahman Department of Rheumatology, Faculty of Medicine, University College, 5 University Street, London WCIE 6JF, UK
  • K. Steinsson Department of Rheumatology and Center for Rheumatology Research, Landspitali, University Hospital, Fossvogur, 108 Reykjavik, Iceland
  • G.S. Alarcón The University of Alabama, Birmingham, 1520 3rd Avenue South, MT 512, AL 5294-3408, USA
  • S. Edworthy University of Calgary, 3330 Hospital Drive, NW, Calgary, Alberta T2N 1N4, Canada
  • J.G. Hanly Division of Rheumatology, Dalhousie University and Capital Health, Second Floor, Nova Scotia Rehabilitation Center, 1341 Summer Street, Halifax, Nova Scotia B3H 4K4, Canada
  • M.A. Dooley University of North Carolina at Chapel Hill, CB #7280 3330 Thurston Building, Chapel Hill, NC 27599-7280, USA
  • L. Criswell Department of Medicine, University of California, Rosalind Russell Medical Research Center for Arthritis, San Francisco, 374 Parnassus Avenue, first floor, San Francisco, CA 94117, USA
  • S. Barr University of Calgary, 3330 Hospital Drive, NW, Calgary, Alberta T2N 1N4, Canada
  • A. Zoma Hairmyres Hospital, East Kilbride, G75 8RG Scotland, UK
  • G. Sturfelt Lund University Hospital, S-22185 Lund, Sweden
  • L. Dreyer Department of Rheumatology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark
  • J.L. Lee Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, 687 Pine Avenue, V Building, Montreal, Quebec, H3A 1A1, Canada
  • J. Labrecque Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, 687 Pine Avenue, V Building, Montreal, Quebec, H3A 1A1, Canada
  • J. Sibley Royal University Hospital, Saskatoon, Saskatchewan, Canada
  • S. Bernatsky Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, 687 Pine Avenue, V Building, Montreal, Quebec, H3A 1A1, Canada and Division of Rheumatology, McGill University Health Centre, 1650 Cedar Ave, Montreal, QC, H3A 1A4, Canada and Division of Rheumatology, McGill University Health Centre, 1650 Cedar Ave, Montreal, QC, H3A 1A4, Canada

DOI:

https://doi.org/10.12970/2310-9874.2014.02.02.1

Keywords:

 Lung cancer, systemic lupus erythematosus, Malignancy.

Abstract

Objective: An increased lung cancer risk in systemic lupus erythematosus (SLE) has been previously suggested. Our objective was to provide an updated analysis of the lung cancer cases from a multi-site international cohort study, including descriptive statistics of the demographics (age, sex, and race/ethnicity) of cases, as well as the histology.

Materials and Methods: Data were obtained from an SLE sample of 16,409 SLE patients across 30 centers. Cancer occurrence was ascertained through linkages with regional tumor registries.

Results: We analyzed 85 lung cancers that had occurred across eight countries. The average age of the SLE patients at lung cancer diagnosis was 60 years and the majority (83.5%) of these cases was female. The average SLE duration at the time of cancer diagnosis was 11 years. Histological type was specified in 32 cases with adenocarcinoma reported as the most common histological type (N=16), followed by squamous cell carcinoma (N=8)and small cell cancer (N=6) and adenosquamous cancers (2).

Conclusion: Our results suggest a similar histological distribution of lung cancers in SLE to that of lung cancer in the general population with a possibly increasing proportion of squamous cell carcinomas.

References

Gayed M, Bernatsky S, Ramsey-Goldman R, Clarke AE, Gordon C. Lupus and cancer. Lupus 2009; 18: 479-85. http://dx.doi.org/10.1177/0961203309102556

Bernatsky S, Ramsey-Goldman R, Clarke A. Exploring the links between systemic lupus erythematosus and cancer. Rheum Dis Clin North Am 2005; 31: 387-402. http://dx.doi.org/10.1016/j.rdc.2005.01.002

Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-7. http://dx.doi.org/10.1002/art.21955

Bernatsky S, Ramsey-Goldman R, Labrecque J. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013; 42: 130-5. http://dx.doi.org/10.1016/j.jaut.2012.12.009

Bin J, Bernatsky S, Gordon C, et al. Lung cancer in systemic lupus erythematosus. Lung Cancer 2007; 56: 303-6. http://dx.doi.org/10.1016/j.lungcan.2007.01.007

Rich AL, Tata LJ, Stanley RA, et al. Hubbard, lung cancer in England: Information from the National Lung Cancer Audit (LUCADA). Lung Cancer 2011; 72: 16-22. http://dx.doi.org/10.1016/j.lungcan.2010.07.002

Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2009, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_ 2009_pops09 Accessed Dec. 2013

Jemal A. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90. http://dx.doi.org/10.3322/caac.20107

Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J. SEER survival monograph: Cancer survival among adults: U.S. SEER program, 1998-2001, Patient and tumor characteristics. National Cancer Institute, SEER Program, NIH Pub No. 07-6215, Bethesda, MD, 2007.

Leitzmann MF, Koebnick C, Abnet CC. Prospective study of physical activity and lung cancer by histologic type in current, former, and never smokers. Am J Epidemiol 2009; 169: 542-53. http://dx.doi.org/10.1093/aje/kwn371

Tran HN, Li Y, Siu S, et al. Predictors of lung cancer: noteworthy cell type differences. Perm J 2013; 17: 23-9. http://dx.doi.org/10.7812/TPP/12-104

Health Canada.Tobacco Use Statistics. Canadian Tobacco Use Monitoring Survey 2011 http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/index-eng.php Accessed Dec. 2013

National Cancer Registry Ireland. Recent trends in lung cancer. Cancer Trends 2009; 1: 1-2.

Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117: 294-9. http://dx.doi.org/10.1002/ijc.21183

Bernatsky S, Joseph L, Boivin J-F. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008; 67: 74-9. http://dx.doi.org/10.1136/ard.2006.069039

Downloads

Published

2014-08-05

Issue

Vol. 2 No. 2 (2014)

Section

Articles